Parkinson's disease clinical trial uses intraoperative mri to guide precision implantation of patients' own autologous replacement neurons

Aspen neuroscience announces mri-guided transplantation approach for aspiro clinical trial with the clearpoint® navigation system san diego , june 20, 2024 /prnewswire/ -- aspen neuroscience, inc. announced today that it is utilizing the mri-guided clearpoint® navigation system for all patients enrolled in the recently launched aspiro phase 1/2a clinical trial for transplantation of dopaminergic neuron precursor cells (danpcs) in patients with parkinson's disease (pd). aspiro is an open label trial to assess safety and tolerability of anpd001, an autologous, dopaminergic neuron cell replacement therapy for participants with moderate to severe pd.
ASPU Ratings Summary
ASPU Quant Ranking